{
  "$schema": "folio-library-entry/v1",
  "id": "10665-331525",
  "blocks": [
    {
      "id": "library/10665-331525/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 6,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "WHO \noperational\nhandbook on \ntuberculosis\nModule 1: Prevention\nTuberculosis preventive treatment\nWHO \noperational\nhandbook on \ntuberculosis\nModule 1: Prevention\nTuberculosis preventive treatment\nWHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment\nISBN 978-92-4-000290-6 (electronic version)\nISBN 978-92-4-000291-3 (print version)\n© World Health Organization 2020\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO \nlicence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-n",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of the WHO operational handbook on tuberculosis preventive treatment (Module 1: Prevention), with title pages, ISBNs, the CC BY-NC-SA licence and disclaimers. It then gives the table of contents, running from the introduction through chapters on target populations, ruling out disease, testing, regimens and safety to annexes on planning and frequently asked questions about TST and IGRAs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "This operational handbook was prepared by Avinash Kanchar with inputs from Dennis Falzon \nand Matteo Zignol under the overall direction of Tereza Kasaeva, Director of the WHO Global TB \nProgramme. The WHO Global TB Programme gratefully acknowledges the contributions of all experts \nand reviewers involved in the production of the latest update of the WHO guidelines on TB preventive \ntreatment on which this handbook is based, as well as other contributors. \nGuideline Development Group of the 2020 guideline revision\nThe Guideline Development Group (GDG) was composed of Mohammed Al Lawati (Consult",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the people behind the TB preventive treatment handbook, including its lead author and WHO Global TB Programme staff. It names the members, co-chairs and observers of the 2020 Guideline Development Group and the External Review Group. It also credits partners who supplied materials and notes that Unitaid funded design and layout.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations & acronyms",
      "pageStart": 8,
      "pageEnd": 10,
      "target": "../sections/sec-001-abbreviations-acronyms.md",
      "narrative": null,
      "content": "1HP\t\none month of daily rifapentine plus isoniazid \n3HP\t\nthree months of weekly rifapentine plus isoniazid \n3HR\t\nthree months of daily rifampicin plus isoniazid\n3TC\t\nlamivudine\n4R\t\nfour months of daily rifampicin monotherapy\n6H\t\nsix months of daily isoniazid monotherapy\n9H\t\nnine months of daily isoniazid monotherapy\nABC\t\nabacavir\nACF \t\nactive TB case finding\nAIDS\t\nacquired immunodeficiency syndrome\nALT\t\nalanine aminotransferase\nART\t\nantiretroviral therapy\nARV\t\nantiretroviral drugs\nAST\t\naspartate aminotransferase\nAZT\t\nzidovudine\nBCG\t\nbacille Calmette-Guérin (vaccine)\nCAD\t\ncomputer aided detecti",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations and acronyms used in the TB preventive treatment handbook, covering regimens such as 3HP and 1HP, antiretroviral drugs, tests and programme terms.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definitions",
      "pageStart": 10,
      "pageEnd": 13,
      "target": "../sections/sec-002-definitions.md",
      "narrative": null,
      "content": "Note: Unless otherwise specified, the definitions listed below apply to the terms as used in this \nhandbook. They may have different meanings in other contexts.\nActive case finding (ACF): is synonymous with systematic screening for TB disease, although it \nnormally implies screening that is implemented outside of health facilities.\nAdolescent: is a person aged 10–19 years.\nAdult: is a person over 19 years of age.\nBacteriologically confirmed TB: is TB diagnosed in a biological specimen by smear microscopy, \nculture or a WHO-approved molecular test such as Xpert MTB/RIF®.\nChild: is a person unde",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines key terms used in the TB preventive treatment handbook, such as age groups, contact, household and close contact, index patient, high transmission setting and latent TB infection. Further definitions cover programmatic management, screening and treatment completion. It closes with a call to deliver preventive treatment to 30 million people by 2022 in line with the UN high-level meeting commitments.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 1. Introduction and approach",
      "pageStart": 13,
      "pageEnd": 19,
      "target": "../sections/sec-003-chapter-1-introduction-and-approach.md",
      "narrative": null,
      "content": "Introduction and approach\nIntroduction\nAbout one fourth of the world’s population is estimated to be infected with M. tuberculosis (1,2). The \nrisk of TB disease after infection depends on several factors, the most important being weakened \nimmunological status (3). The vast majority of infected individuals show no signs or symptoms of TB \nand are not infectious, although they have an increased risk of progressing to TB disease and becoming \ninfectious. On average, about 5–10% of those infected will develop TB disease over the course of their \nlives, most of them within the first five years af",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the TB preventive treatment handbook, explaining that about a quarter of people worldwide are infected with M. tuberculosis and that people with HIV and contacts of TB patients are at highest risk. It places programmatic management of preventive treatment within the End TB Strategy and the 2018 UN high-level meeting targets, noting low coverage so far. It describes the handbook's purpose, intended users and approach of guiding countries through decision points. A box summarises WHO recommendations and urges governments and donors to expand access.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/figure-vfig-p015",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../figures/vfig-p015.webp",
      "narrative": "draft",
      "content": "Two diagrams. Figure 1.1 is a flowchart from 'Target population' to 'Active TB case finding', splitting into 'Presumptive TB' (test for TB disease; if TB confirmed, provide TB treatment; if no TB, give TPT) and 'No TB' (testing for TB infection*, assess for TPT, give TPT), all ending in 'Systematic follow-up'; the footnote reads '*PLHIV and child household contacts aged < 5 years'. Figure 1.2 is a ring of six circles around 'Additional funding': national policy or guidelines, health infrastructure, human resource capacity and training, demand creation, supervision and monitoring, and review and policy adjustment.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1.1: Recommendations in the WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment¹",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../tables/table-1-1.csv",
      "narrative": "draft",
      "content": "The table lists the 18 recommendations of the WHO consolidated guidelines on tuberculosis preventive treatment. They are grouped under identifying populations for LTBI testing and TB preventive treatment (people living with HIV, household contacts, other people at risk), algorithms to rule out active TB disease, testing for LTBI, and TB preventive treatment options.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 2. Identification of populations for TB preventive treatment",
      "pageStart": 19,
      "pageEnd": 31,
      "target": "../sections/sec-004-chapter-2-identification-of-populations-for-tb-p.md",
      "narrative": null,
      "content": "populations for TB preventive \ntreatment\nDecision point on target populations for systematic \ntesting and TPT\nWhich of the at-risk populations are priority targets for the programmatic scale-up of TPT, based on \nyour country context?\nThe WHO guidelines on TPT recommends target populations fulfilling one or more of the following \ncriteria for PMTPT (12):\n•\t High prevalence of TB infections\n•\t High risk of progression to TB disease\n•\t High incidence of TB disease compared to the general population, indicating high TB transmission \nsetting\n•\t Benefits of TPT outweighing potential risk of acquirin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses which at-risk populations countries should prioritise for systematic testing and TB preventive treatment, based on infection prevalence, progression risk and transmission. It sets out the rationale and WHO recommendations for people living with HIV, including children and infants, household contacts of all ages, and clinical risk groups such as patients on dialysis or anti-TNF therapy. It also covers prisoners, health workers, migrants and other groups that may be considered case by case. The chapter ends with implementation considerations for contact investigation and a call to invest in it.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/figure-vfig-p025",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../figures/vfig-p025.webp",
      "narrative": "draft",
      "content": "Diagram (Fig. 2.1) pairing five steps of contact investigation with indicative costing items: identification of contacts (health care worker time to interview the index TB patient, travel to the household or workplace); clinical evaluation (worker time for evaluation and follow-up, enabler or travel support for contacts); testing for TB disease or eligibility for TPT (travel support to the testing site, specimen collection transport); provide access to TPT (worker time for referral and follow-up on TPT/TB treatment initiation and social support); and recording and reporting (data capture tools such as the WHO Prevent TB mobile application, worker time). The render also includes the preceding key point and text on strengthening household contact investigation.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-vfig-p026",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../figures/vfig-p026.webp",
      "narrative": "draft",
      "content": "Diagram (Fig. 2.2) of six columns of blue boxes listing building blocks for contact investigation: prioritize contact investigation, define roles and responsibility, provide standard protocols and procedures, guidance on recording and reporting; health care worker, community workers/volunteers, former TB patients; counselling about the importance of contact investigation, risk assessment, TPT and adverse events management, interview techniques, follow-up and basic data collection; support for home visits/travel to health facility, additional human resources, enablers and incentives, information and communication tools; conduct early interview (one week), use local language, include environment assessment, include family counselling, referral for testing and starting TPT; and provide disclosure counselling (family/contact), ensure respectful treatment, obtain consent for investigation. Column headings are not shown in this render.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 3. Ruling out TB disease before TB preventive treatment",
      "pageStart": 31,
      "pageEnd": 39,
      "target": "../sections/sec-005-chapter-3-ruling-out-tb-disease-before-tb-preven.md",
      "narrative": null,
      "content": "before TB preventive treatment\nDecision point on how to exclude TB disease before \noffering TPT\nHow can TB disease be reliably ruled out among target populations identified for TPT?\nOffering TPT to someone who has TB disease can delay the resolution of disease and favour the \nemergence of drug resistance. Thus, excluding TB disease before initiating TPT is one of the critical \nsteps in the preventive TB care pathway. This chapter covers WHO recommendations as well as key \npolicy and implementation considerations in the development of national algorithms to rule out TB \ndisease, mindful of the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how to rule out TB disease before starting preventive treatment, since treating active disease this way risks delays and drug resistance. It reviews the sensitivity of symptom screening in different groups and the added value of chest radiography, citing related WHO recommendations. It discusses algorithms combining symptoms, imaging and tests for people with HIV, contacts and other risk groups. It ends with practical steps such as expanding rapid diagnostics, specimen transport and standard operating procedures.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3.1: Key steps in ruling out TB and considering TPT",
      "pageStart": 35,
      "pageEnd": 35,
      "target": "../tables/table-3-1.csv",
      "narrative": "draft",
      "content": "The table sets out the key steps in ruling out TB disease and considering TB preventive treatment, from clinical symptom-based screening to chest radiography, diagnostic testing, testing for TB infection, contraindications and counselling. Symptom screening criteria are given separately for adults and adolescents living with HIV, children living with HIV, and HIV-negative household contacts and clinical at-risk populations; the other steps apply to all groups.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 4. Testing for TB infection",
      "pageStart": 39,
      "pageEnd": 47,
      "target": "../sections/sec-006-chapter-4-testing-for-tb-infection.md",
      "narrative": null,
      "content": "infection\nDecision point on role of TST or IGRA \nWhat is the role of testing for TB infection before starting TPT among target populations prioritized \nby the ministry of health?\nJust as excluding TB disease is a critical step before starting TPT, confirming TB infection before starting \nTPT may increase the certainty that individuals targeted for TPT would benefit from it. However, there \nis no gold standard test to diagnose TB infection. Currently available tests are indirect and require the \nperson to mount an immune response in order to work properly. A positive test result by either metho",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses the role of the tuberculin skin test and interferon-gamma release assays before preventive treatment, stressing there is no gold standard for TB infection. It explains how each test works, their limitations and false negatives, and when testing need not delay treatment, such as for people with HIV and young child contacts. It covers test choice, logistics and programme considerations, and includes an algorithm flowchart for deciding on preventive treatment. It ends with a call to invest in shorter regimens.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4.1: Characteristic features of TST and IGRA (43)",
      "pageStart": 42,
      "pageEnd": 43,
      "target": "../tables/table-4-1.csv",
      "narrative": "draft",
      "content": "The table compares the tuberculin skin test (TST) and interferon-gamma release assays (IGRA) for detecting TB infection. Rows cover test requirements, potential inaccuracy, advantages, challenges and the situations in which each test is preferred.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-vfig-p044",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../figures/vfig-p044.webp",
      "narrative": "draft",
      "content": "Flowchart (Fig. 4.1) of the algorithm for TB screening and TPT with three entry groups. People who are HIV positive are asked about any symptom of current cough, fever, weight loss or night sweats; household contacts are asked if symptomatic, and those without symptoms are split into under 5 years and 5 years and over; other risk groups go to TST or IGRA, where a positive or unavailable result leads to chest radiography and a negative result ends the pathway. Symptoms or an abnormal chest radiograph lead to 'Investigate for active TB'; people with no active TB, a normal or unavailable radiograph, or no symptoms are assessed for 'Preventive treatment contraindicated?', ending in 'Defer preventive treatment' or 'Give preventive treatment', followed by 'Follow up for active TB as necessary, even for patients who have completed preventive treatment'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 5. TB preventive treatment",
      "pageStart": 47,
      "pageEnd": 67,
      "target": "../sections/sec-007-chapter-5-tb-preventive-treatment.md",
      "narrative": null,
      "content": "treatment\nDecision point on choice of TB preventive treatment \nWhich of the WHO recommended TPT regimens should be used for different individuals in the country?\nTPT regimen recommendation and availability\nTPT broadly falls into two categories: (i) isoniazid monotherapy for six or nine months, or (ii) rifamycin-\nbased shorter preventive treatment, on the assumption that the infecting strain is susceptible to these \nmedicines. Isoniazid preventive treatment (IPT) for six months has been the most widely used regimen \nunder programmatic conditions and has emerged as a standard for TPT for both ad",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers the choice among WHO-recommended TB preventive treatment regimens, from six or nine months of isoniazid to shorter rifamycin-based options such as 3HP, 3HR, 1HP and 4R. It reviews evidence on efficacy and completion rates and explains the 2020 changes to recommended durations. It also addresses dosing, regimens for contacts of drug-resistant TB, pregnancy, children and drug interactions with antiretrovirals and other medicines. The chapter closes with guidance on people who use drugs and a call to raise demand for preventive treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.2: Recommended dosages of medicines for TB preventive treatment",
      "pageStart": 52,
      "pageEnd": 53,
      "target": "../tables/table-5-2.csv",
      "narrative": "draft",
      "content": "The table gives the recommended dosages of medicines for each TB preventive treatment regimen (6H/9H, 4R, 3HR, 3HP, 1HP and six months of levofloxacin for MDR-TB contacts) by age and weight band. For 3HR and 3HP it includes weight-band tables showing the number of tablets of each medicine and formulation.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5.3: Preventive TB treatment completion",
      "pageStart": 58,
      "pageEnd": 58,
      "target": "../tables/table-5-3.csv",
      "narrative": "draft",
      "content": "The table summarizes the recommended TB preventive treatment regimens and suggested criteria for assessing treatment completion. For each regimen it gives the total duration in months, the expected number of doses, 80% of recommended doses, and the extended time allowed for completion (treatment duration plus 33%).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 6. Safety, management of adverse reactions and other drug-related issues in TB preventive treatment",
      "pageStart": 67,
      "pageEnd": 83,
      "target": "../sections/sec-008-chapter-6-safety-management-of-adverse-reactions.md",
      "narrative": null,
      "content": "of adverse reactions and \nother drug-related issues in \nTB preventive treatment \nWHO has for long recommended the use of TPT for populations at risk of TB, particularly PLHIV \nand child household contacts of TB patients. However programmatic scale-up of TPT has remained \nlimited in most high TB and HIV burden countries due to other competing priorities. Concerns about \nthe efficacy and safety of TPT and interactions with other medicines, particularly ARVs, may also be \nbarriers to programmatic scale-up. Other frequently raised questions are about the potential for TPT \nto increase TB drug-resi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Addresses safety concerns that hinder scale-up of TB preventive treatment, including adverse drug reactions, monitoring and counselling. It tabulates known adverse events for isoniazid and rifamycins and details hepatotoxicity risks and their management. Further sections discuss interactions with other medicines, adherence, the durability of protection and fears that preventive treatment fosters drug resistance. It cites trial data finding no significant rise in rifampicin resistance and calls for patient support to ensure completion.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.1: Likely adverse events with drugs used for TPT",
      "pageStart": 68,
      "pageEnd": 68,
      "target": "../tables/table-6-1.csv",
      "narrative": "draft",
      "content": "The table lists the likely adverse events of the drugs used for TB preventive treatment. For isoniazid, rifampicin and rifapentine it separates known adverse events from rare adverse events.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.2: Summary of adverse events and treatment withdrawals because of adverse events",
      "pageStart": 70,
      "pageEnd": 70,
      "target": "../tables/table-6-2.csv",
      "narrative": "draft",
      "content": "The table summarizes, by TB preventive treatment regimen (6H, 9H, 3HP, 3–4R, 3–4HR), the number of participants in studies included in a systematic review and the median percentage (minimum–maximum) experiencing adverse events. Results are given separately for any adverse events, grade 3–4 adverse events, and withdrawal from the study because of adverse events.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/table-008",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.3: Management of potential adverse reactions following treatment with 3HP⁹",
      "pageStart": 72,
      "pageEnd": 73,
      "target": "../tables/table-6-3.csv",
      "narrative": "draft",
      "content": "The table guides the management of potential adverse reactions after treatment with 3HP (weekly isoniazid plus rifapentine). For each adverse event it indicates when to stop and consider reintroducing treatment with caution and when to stop and not reintroduce.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/table-009",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6.4: Common drug–drug interactions of isoniazid and rifamycins",
      "pageStart": 75,
      "pageEnd": 77,
      "target": "../tables/table-6-4.csv",
      "narrative": "draft",
      "content": "The table lists common drug–drug interactions of isoniazid and rifamycins by medication class, with example drugs. Arrows show where isoniazid inhibits metabolism and increases blood levels, and where rifamycins accelerate metabolism and decrease blood levels.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 7. Adherence to TB preventive treatment",
      "pageStart": 83,
      "pageEnd": 93,
      "target": "../sections/sec-009-chapter-7-adherence-to-tb-preventive-treatment.md",
      "narrative": null,
      "content": "preventive treatment \nDecision point on strategies to promote adherence \nto TPT\nWhat strategies should national programmes adopt to ensure adherence to the prescribed regimen \nby all individuals started on TPT?\nAdherence to treatment is a complex behaviour that is influenced by many factors such as personal \nmotivation, beliefs about health, risks and benefits from treatment, comorbidities, competing demands \nthat conflict with the taking of medicine, family environment, complexity of the drug regimen, drug \ntoxicity, trust and relationship with the health provider (58). Effective person-centr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Chapter 7 of a WHO operational handbook on tuberculosis preventive treatment (TPT) addresses how national programmes can help people complete their prescribed regimen. It explains that adherence depends on many personal, social and treatment-related factors and lists person-centred measures such as confidential counselling, education in the person's language, involving families and giving clear advice on side-effects. It also covers warning people that TB disease can still develop during TPT, along with options such as reminders, digital adherence technologies, shorter regimens and community support. The chapter closes by urging investment in monitoring and in digital tools for recording and reporting TPT services.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/figure-vfig-p093",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 93,
      "pageEnd": 93,
      "target": "../figures/vfig-p093.webp",
      "narrative": "draft",
      "content": "Pyramid diagram (Fig. 8.1) of the use of health data at different levels of the health system. From base to apex: person-centred patient care/management, including patient monitoring; routine cascade data reviews for programme improvement, from national to facility level, including aggregate and individual-level/case surveillance data; national strategic plans and accountability towards multi-year goals and targets; and accountability towards global/UN commitments, Sustainable Development Goals. Side labels on the left are cut off in this render.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 8. Monitoring and evaluation",
      "pageStart": 93,
      "pageEnd": 103,
      "target": "../sections/sec-010-chapter-8-monitoring-and-evaluation.md",
      "narrative": null,
      "content": "evaluation\nDecision point on minimum data for routine \nrecording and reporting\n•\t What data should be routinely captured and reported to the national level for \nprogramme management?\n•\t What is the minimum dataset needed to monitor individual case management and monitor \nprogress across the TPT pathway?\n•\t What tools and methods should be used to facilitate data collection and reporting?\nMonitoring and evaluation (M&E) play an important role in patient care and in assessing national \nprogrammes and global response (Fig. 8.1). Accurate recording and reporting of programmatic \ndata informs manag",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Chapter 8 of the TPT handbook sets out what data should be routinely recorded and reported, the minimum dataset for following people along the TPT cascade, and the tools for collecting it. It explains how monitoring and evaluation serve patient care, national programme management and global accountability, with examples such as counting household contacts evaluated and people completing TPT. Material on the cascade of care tracks numbers targeted, evaluated, eligible, started and completed, and explains how to estimate target populations among people living with HIV and household contacts. The chapter ends with a reminder that programmes must counsel people to make informed choices and protect them from stigma.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/figure-vfig-p094",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 94,
      "pageEnd": 94,
      "target": "../figures/vfig-p094.webp",
      "narrative": "draft",
      "content": "Arrow diagram (Fig. 8.2) of critical numbers to monitor along the TPT pathway, in five boxes from left to right: # target population, # evaluated for eligibility, # eligible for TPT*, # started TPT and # completed TPT.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Chapter 9. Ethics and TB preventive treatment",
      "pageStart": 103,
      "pageEnd": 106,
      "target": "../sections/sec-011-chapter-9-ethics-and-tb-preventive-treatment.md",
      "narrative": null,
      "content": "Chapter 9. Ethics and TB \npreventive treatment\nDecision on ethical issues in TPT implementation\nWhat are ethical considerations and related actions for programme management of TPT?\nImplementation considerations \nIn general, only about 5–10% of people infected with M. tuberculosis will develop TB disease at some \npoint in their lifetime. The risk of TB infection progressing to TB disease is much higher for some \ngroups, such as PLHIV, very young children and people who have just recently acquired infection. \nTreatment always carries some risk of adverse drug reactions, so understanding the indi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Chapter 9 of the TPT handbook discusses ethical considerations in delivering preventive treatment to people who are not ill or infectious. It stresses weighing individual benefits against harms, limiting testing and treatment to groups at proven risk, and ensuring that taking TPT is a voluntary, informed choice grounded in human rights. It also addresses equity, confidentiality, stigma and the need for adequate communication resources so that individuals and communities can decide autonomously.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1. List of key messages",
      "pageStart": 106,
      "pageEnd": 116,
      "target": "../sections/sec-012-annex-1-list-of-key-messages.md",
      "narrative": null,
      "content": "Messages for the ministry of health\n•\t National governments have made a commitment at the first ever UN High Level Meeting on TB on \n26th September 2018 towards “preventing tuberculosis for those most at risk of falling ill through the \nrapid scaling up of access to testing for tuberculosis infection, according to the domestic situation, and \nthe provision of preventive treatment, with a focus on high-burden countries, so that at least 30 million \npeople, including 4 million children under 5 years of age, 20 million other household contacts of people \naffected by tuberculosis, and 6 million pe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1 of the TPT handbook lists key messages for ministries of health and for health care workers. Messages for ministries recall commitments made at the 2018 UN High-Level Meeting on TB and the End TB Strategy targets, and present TPT as an effective intervention that substantially lowers the risk of TB disease. Messages for health workers cover shorter rifapentine- or rifampicin-based regimens, which are reported to be easier to complete, plus counselling before treatment, ruling out TB disease and managing adverse events. Notes point to funding sources and to the Global Drug Facility for medicines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p110-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 110,
      "pageEnd": 110,
      "target": "../images/img-p110-1.webp",
      "narrative": "draft",
      "content": "Illustration from the patient leaflet on TB preventive treatment showing a group of six people of different ages, including a woman in a blue sari, a man in an orange robe, a woman in a blue headscarf, a young man, a girl and a small boy.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p110-4",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 110,
      "pageEnd": 110,
      "target": "../images/img-p110-4.webp",
      "narrative": "draft",
      "content": "Diagram of three person icons, each above an empty box with a pink arrow that runs downward and branches to the right; the size of the side branch decreases from left to right while the downward arrow widens. No text labels are visible in the image.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p110-5",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 110,
      "pageEnd": 110,
      "target": "../images/img-p110-5.webp",
      "narrative": "draft",
      "content": "Illustration of a young woman in profile exhaling a cloud of small particles against a dark circular background, from the patient leaflet on TB preventive treatment.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p111-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 111,
      "pageEnd": 111,
      "target": "../images/img-p111-1.webp",
      "narrative": "draft",
      "content": "Illustration of a health care worker in a white coat with a stethoscope, holding a clipboard, from the patient leaflet.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p112-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 112,
      "pageEnd": 112,
      "target": "../images/img-p112-1.webp",
      "narrative": "draft",
      "content": "Illustration of a person placing a pill in his mouth, from the patient leaflet.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p112-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 112,
      "pageEnd": 112,
      "target": "../images/img-p112-2.webp",
      "narrative": "draft",
      "content": "Red ribbon, the symbol of HIV awareness, from the patient leaflet.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p112-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 112,
      "pageEnd": 112,
      "target": "../images/img-p112-3.webp",
      "narrative": "draft",
      "content": "Illustration of a woman in a yellow headscarf with a finger on her chin, looking thoughtful, from the patient leaflet.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p113-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 113,
      "pageEnd": 113,
      "target": "../images/img-p113-1.webp",
      "narrative": "draft",
      "content": "Illustration of a pregnant woman holding her abdomen, from the patient leaflet.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 2. Coordination mechanisms to support PMTPT",
      "pageStart": 116,
      "pageEnd": 118,
      "target": "../sections/sec-013-annex-2-coordination-mechanisms-to-support-pmtpt.md",
      "narrative": null,
      "content": "mechanisms to support PMTPT\nThe ministry of health should create and strengthen a joint national coordinating body and/or national \ntechnical expert working group to support national scale-up of PMTPT through implementation of \nthe latest global guidelines. Alternatively, the mandate of an existing body that can serve both a \nmanagement and technical function may be expanded to advise the ministry of health and national TB, \nHIV and other programmes. This will guide and support the efforts of governments towards fulfilling \ntheir national commitments on PMTPT made at the first UN High Level Me",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 2 recommends that ministries of health set up or strengthen a joint national coordinating body and a technical expert working group to drive scale-up of programmatic TPT management. It outlines their terms of reference, membership and secretariat arrangements, and asks TB and HIV programmes to fund regular meetings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 3. Costing considerations for programmatic management of TB preventive treatment",
      "pageStart": 118,
      "pageEnd": 120,
      "target": "../sections/sec-014-annex-3-costing-considerations-for-programmatic.md",
      "narrative": null,
      "content": "for programmatic management \nof TB preventive treatment \nWhen preparing a budget for PMTPT, the following considerations need to be made given that these \nare major cost determinants:\n•\t Estimated burden\n\t– Populations of each target group (PLHIV, contacts, clinical risk groups, other risk groups)\n\t– Number of households and other sites (health facilities, ARV centres) to be covered for expansion \nof TPT activities\n•\t Investigation of target populations\n\t– Test for TB infection (TST/IGRA) as per national policy (such as test equipment general supplies, \nprocurement fees for supplies, specimen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 3 lists the main cost drivers to consider when budgeting for programmatic TPT management. These include target population sizes, tests for TB infection and chest radiography, human resources, medicines and procurement, and recording and reporting systems.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 4. Planning checklist for PMTPT",
      "pageStart": 120,
      "pageEnd": 122,
      "target": "../sections/sec-015-annex-4-planning-checklist-for-pmtpt.md",
      "narrative": null,
      "content": "PMTPT\nActivity\nCurrent status\nNext Steps\nNational TB Strategic Plan (NSP)\n \n \nPlanning meeting of key stakeholders as a PMTPT \ncoordinating mechanism\n \n \nFunding estimates to implement new guidelines\n \n \nNational PMTPT indicators agreed\nNSP revision\n \n \nGuidelines update\n \n \nNational technical expert group meeting \n \n \nIdentification of (priority) risk groups\n \n \nDiagnostic algorithm (role of test for TB infection and \nchest radiography)\n \n \nTreatment options (regimens, criteria for choice)\n \n \nDissemination to key stakeholders\n \n \nExpansion plan\n \n \nMultistakeholder group meeting to support T",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 4 provides a planning checklist for programmatic TPT management, with columns for current status and next steps. Activities covered include strategic planning, guideline updates, coverage of risk groups, training, advocacy, community outreach and medicine supply and stock management.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 5. Answers to frequently asked questions on TST",
      "pageStart": 122,
      "pageEnd": 127,
      "target": "../sections/sec-016-annex-5-answers-to-frequently-asked-questions-on.md",
      "narrative": null,
      "content": "asked questions on TST\nWhat is tuberculin skin testing (139)?\nTuberculin skin test (TST), first introduced in 1908, remains the most commonly used test for TB \ninfection in the world due to its low cost and feasibility to implement in low resource settings. There \nis no need for complex laboratory equipment or procedures or trained technicians, although training \nis required for proper intradermal administration of the tuberculin purified protein derivative (PPD). \nIntradermal injection of tuberculin causes delayed hypersensitivity reaction if a person has TB infection. \nThe T-cells in such in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5 answers frequently asked questions about the tuberculin skin test (TST) for TB infection. It explains how the test works, the standard tuberculin doses and intradermal injection technique, and how to read and measure the induration, including the ballpoint pen method. It also covers interpreting results, causes of false-positive and false-negative readings, and the limited effect of BCG vaccination given at birth.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 6. Answers to frequently asked questions on IGRAs",
      "pageStart": 127,
      "pageEnd": 130,
      "target": "../sections/sec-017-annex-6-answers-to-frequently-asked-questions-on.md",
      "narrative": null,
      "content": "Annex 6. Answers to frequently \nasked questions on IGRAs \nWhat are IGRAs?\nInterferon gamma release assays (IGRAs) are whole-blood tests that can aid in diagnosing M. tuberculosis \ninfection (43). Like TST, IGRAs cannot differentiate between TB infection and TB disease. WHO reviewed \navailable evidence around the two most widely used IGRAs in 2017, QuantiFERON®-TB Gold In-Tube \ntest (QFT-GIT) and T-SPOT.TB test (T-Spot), to facilitate recommendation on their use to identify \nindividuals having TB infection. \nHow do IGRAs work? \nWhite blood cells from individuals infected with M. tuberculosis re",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 6 answers frequently asked questions about interferon-gamma release assays (IGRAs) for TB infection, including the two commercial tests WHO reviewed in 2017. It explains that IGRAs measure interferon-gamma released by white blood cells exposed to M. tuberculosis-specific antigens absent from BCG strains, and that like TST they cannot separate infection from disease. It also covers specimen handling, interpretation and how to handle discordant or borderline results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 130,
      "pageEnd": 140,
      "target": "../sections/sec-018-references.md",
      "narrative": null,
      "content": "1. \t Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical \nmodelling. PLOS Med. 2016;13(10):e1002152. \n2. \t Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review \nand meta-analysis. Eur Respir J. 2019;54(3):1900655. \n3. \t Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J \nMed. 2015;372(22):2127–35. \n4. \t Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and \nadolescence. Am J Epidemio",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the TPT handbook, citing studies on latent TB burden and prognosis, contact investigation and WHO strategies and guidelines, followed by the text of a patient information leaflet on TB infection and preventive treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-331525/blocks/figure-img-p140-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 140,
      "pageEnd": 140,
      "target": "../images/img-p140-1.webp",
      "narrative": "draft",
      "content": "ISBN barcode for 9789240002906.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
